UMIP Social Enterprise Ignition Funding Opportunity Round 2 – Now Open

Written by UMIP on . Posted in News

Following the success of Round 1 we are now seeking to ignite a new generation of individuals interested in pursuing a social business:Layout 1

  • Are you currently working or studying at The University of Manchester or a recent graduate?
  • Is your idea likely to benefit the public or community, or be an entrepreneurial solution to a societal, healthcare or environmental problem?
  • Do you have the passion to drive your idea forward and set up a project or social business?

Awards:

Funding from £500 – £2000 is available, for individuals to try out or grow their entrepreneurial ideas. This might mean finding out if your idea is viable, learning more about what is needed to develop the idea by testing the project on a small scale, right through to more robust road-testing of the idea. We also provide one to one support to assist you with your applications and informative workshops for successful applicants.

Eligibility:

The funding opportunity is open to all members of staff, academics, research students and recent graduates (graduated within the last 2 years) from The University of Manchester.

Key Dates:Soc-Ent-Tree-Blue-538

  • Closing date for applications is Friday 24th March 2017
  • Successful applicants will be informed by Friday 31st March 2017

Click Social Enterprise Ignition Fund Application Form-final to download an application form and contact Social.Enterprise@umip.com for further information.

Unlocking the potential of your IP – understanding the value of the intellectual property in research

Written by UMIP on . Posted in News

IPO

Unlocking the potential of your IP – understanding the value of the intellectual property in research

Date: Tuesday 21st March (afternoon).

Location: The University of Manchester Innovation Centre (UMIC), The Core Technology Facility, 46 Grafton Street, Manchester, M13 9NT.

Who? All PhD students and Early Career Researchers from across the N8 Partnership universities.

Can you take your research further? The Intellectual Property Office (IPO) has worked with The University of Manchester Intellectual Property (UMIP) and the N8 Research Partnership to develop a half-day session that provides an insight into the potential opportunities to maximise the impact of your research.

Knowledge exchange, commercialisation and collaboration present different pathways to realise impact but they also present different challenges.

This session will explain how to navigate the IP environment and provide real insights from those who have been through the highs and lows of the process.

We’ll email you nearer the time with information on how to book your place. If you have any queries in the meantime please email us.

 

ipo 2

   

F2G Ltd Receives European Orphan Drug Designation for its Lead Candidate F901318

Written by UMIP on . Posted in News

MANCHESTER, UK – 09 January 2017 – F2G Ltd, a UK Biotech developing novel therapies for life threatening fungal infections, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted orphan drug status to its lead clinical candidate, F901318, for the treatment of invasive Aspergillosis and rare mould infections caused by Scedosporium species.

Orphan drug designation will allow F901318 up to ten years market exclusivity following market authorisation in the EU.

F901318 is the first member of a novel class of systemic antifungal agents targeting life threatening mould infections and acting through a completely novel cellular target. F901318 is being developed for both intravenous and oral formulations and will enter Phase II clinical development in mid-2017.

Dr John H. Rex, Chief Medical Officer, F2G Ltd, said: “Given the global acknowledgement of increasing resistance of moulds to the azole antifungal class, we are delighted that the EMA has granted orphan drug status to F901318. We believe this agent will offer important therapeutic options to clinicians treating these deadly infections.”

Ian Nicholson, Chief Executive Officer, F2G Ltd, added: “Receiving the European orphan drug designation for F901318 offers certain benefits and incentives, including marketing exclusivity, that are strategically important from a regulatory and commercial perspective. The positive decision of the EMA orphan drug committee is further validation of F901318 and our development program as we look forward to accelerating our Phase II clinical programme this year. ”

###

About European Union (EU) Orphan Drug Designation: The European Commission grants orphan drug designation status to provide incentives to develop medicinal products to treat, prevent or diagnose diseases or conditions that affect no more than five in 10,000 persons in the European Union.

About F2G Ltd: F2G is a world-leading UK biotech company focused on the discovery and development of novel therapies to treat life threatening invasive fungal infections, with experienced management & board. F2G has discovered and developed a completely new class of antifungal agents called the orotomides. The orotomides are active against Aspergillus and other rare and resistant moulds and act via a completely different mechanism than currently marketed antifungal agents. Due to their new mechanism of action, orotomides are active against fungal infections resistant to current therapies, a growing problem globally. A limited Phase II study for F901318 is planned imminently with pivotal registration trials in Invasive Aspergillosis planned for 2017 based on an accelerated regulatory pathway agreed with the relevant agencies. F901318 is being developed both as IV and oral formulations and promises to have a safe and well-tolerated profile. The company recently announced a $60 million financing to develop its pipeline of novel therapies to treat life threatening invasive fungal infections.

AMBS Ignition Funding Opportunity- Deadline Fast Approaching

Written by UMIP on . Posted in News

We are seeking to inspire the next generation of individuals or teams with entrepreneurial ideas:Layout 1

  • Are you currently working or studying at AMBS or a recent graduate?
  • Is your idea likely to be an entrepreneurial or innovative solution to a business, societal or environmental problem?

Awards:

Funding from £500 – £2000 is available, for individuals to try out or grow their entrepreneurial ideas. This might mean finding out if your idea is viable, learning more about what is needed to develop the idea by testing the project on a small scale, right through to more robust road-testing of the idea. We also provide one to one support to assist you with your applications and informative workshops for successful applicants.

Eligibility:

The funding opportunity provided by UMIP and MEC is open to all AMBS members of staff, research students (inc. DBA, MBA) and recent graduates (graduated within the last 2 years).

Key Dates:

  • Closing date for applications is Friday 20thJanuary 2017
  • Successful applicants will be informed by Friday 3rdFebruary 2017

Click AMBS Ignition Fund Application Form-final to download an application form and contact ignitionawards@umip.com for further information.

UMI3 Ltd appoints Dr. Luke Hakes as its new Chairman

Written by UMIP on . Posted in News

Dr. Luke Hakes

Dr. Luke Hakes

The University of Manchester’s Innovation Company (UMI3 Ltd) is pleased to announce the appointment of Dr. Luke Hakes as its new independent Chairman, following a search exercise by the University (advised by Odgers Berndtson – nationally recognised headhunters).

Luke will commence his role on 1st January 2017. A triple graduate of the University in biochemistry with biotechnology; bioinformatics; and computational genetics, Luke completed a PhD in 2006. He is currently Investment Director at venture capital firm, Octopus Ventures, based in the City of London. Over the last eight years Luke has advised and been a board member of a number of University spin-out companies. In addition he has held numerous non-executive directorships at start up and growth companies and has considerable experience of building and exiting businesses in the disruptive technology arena.

Outside of Octopus, Luke is an angel investor and advisor to a number of early stage companies with a particular interest in the Artificial Intelligence and Genomics spaces.

Dr. Hakes comments: “I am delighted to be joining UMI3 as Chairman. Universities play a hugely important role in fostering innovation and talent and nowhere is this more true than at The University of Manchester. I am incredibly excited to work with the fantastic team at UMI3 to support its continued growth and success.”

Clive Rowland, UMI3 CEO, comments: “Luke’s appointment is an important step for us as we embark on a new business plan in an exciting time of development for the University and the Northern Powerhouse. Luke’s enthusiasm for technology venturing, his commitment to help the University further enhance its standing in this area and his expertise and wide investor networks all bring a new and refreshing dimension to our approach which is crucial for our next phase.”

Luke succeeds Dr Rajagopal in the role.

UMIP - REPUTATION AND VALUE THROUGH INTELLECTUAL PROPERTY®

Privacy Policy / Terms and Conditions / © Copyright 2015 The University of Manchester Intellectual Property / Created by HTP Digital Marketing Agency

The University of Manchester Intellectual Property ("UMIP") acts solely as agent for the University in relation to any matter relating to intellectual property ("IP") and know how created at the University. This is whether such IP is created by employees, students or others. UMIP does not represent anyone else in such matters. If anyone else requires advice in relation to such IP then they must take their own independent legal advice.